US 12,440,441 B2
Pharmaceutical solution of amlodipine
Jayanta Kumar Mandal, Ahmedabad (IN); Malay Patel, Ahmedabad (IN); Swati Nagar, Amreli (IN); and Michael Paul DeHart, Winterville, NC (US)
Assigned to LIQMEDS WORLDWIDE LIMITED, Weedon (GB)
Filed by LIQMEDS WORLDWIDE LIMITED, Hayes (GB)
Filed on Jan. 8, 2025, as Appl. No. 19/013,003.
Application 19/013,003 is a continuation of application No. 18/653,190, filed on May 2, 2024, granted, now 12,226,528.
Application 18/653,190 is a continuation of application No. 18/339,267, filed on Jun. 22, 2023, granted, now 12,005,141, issued on Jun. 11, 2024.
Application 18/339,267 is a continuation of application No. 17/840,829, filed on Jun. 15, 2022, granted, now 11,723,866, issued on Aug. 15, 2023.
Application 17/840,829 is a continuation of application No. 17/575,693, filed on Jan. 14, 2022, granted, now 11,458,095, issued on Oct. 4, 2022.
Application 17/575,693 is a continuation of application No. 17/183,553, filed on Feb. 24, 2021, granted, now 11,253,474, issued on Feb. 22, 2022.
Claims priority of provisional application 63/144,021, filed on Feb. 1, 2021.
Prior Publication US 2025/0195425 A1, Jun. 19, 2025
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 9/08 (2006.01); A61K 31/4418 (2006.01); A61K 47/10 (2017.01); A61K 47/26 (2006.01)
CPC A61K 9/08 (2013.01) [A61K 31/4418 (2013.01); A61K 47/10 (2013.01); A61K 47/26 (2013.01)] 30 Claims
 
1. An oral liquid pharmaceutical formulation, comprising:
about 1 mg/mL amlodipine, as amlodipine besylate;
at least one pharmaceutically acceptable excipient;
a water content of less than or equal to about 5% w/w; and
a liquid vehicle.